The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib study of anetumab ravtansive in combination with immunotherapy or immunotherapy plus chemotherapy in mesothelin-enriched advanced pancreatic adenocarcinoma: NCI10208.
 
Pavlina Spiliopoulou
No Relationships to Disclose
 
Anup Kasi
Honoraria - OncLive
Research Funding - Astellas Pharma (Inst); Bavarian Nordic (Inst); Cardiff Oncology (Inst); FibroGen (Inst); Geistlich Pharma (Inst); Halozyme (Inst); Novocure (Inst); Rafael Pharmaceuticals (Inst); TESARO (Inst)
Travel, Accommodations, Expenses - Halozyme; Rafael Pharmaceuticals
 
Laith I. Abushahin
Research Funding - Celgene (Inst)
 
Dana Backlund Cardin
Honoraria - OncLive/MJH Life Sciences
Consulting or Advisory Role - Clarivate; Rafael Pharmaceuticals
Research Funding - Array BioPharma (Inst); Celgene (Inst); Corcept Therapeutics (Inst); EMD Serono (Inst); Incyte (Inst); Lilly (Inst); Novartis (Inst); Rafael Pharmaceuticals (Inst); XBiotech (Inst)
Travel, Accommodations, Expenses - ipsen
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; Fulgent Genetics; G1 THerapeutics; GlaxoSmithKline; Isofol Medical; Jazz Pharmaceuticals; Merck Serono; Oncocyte; Roche
Consulting or Advisory Role - Bayer; BMS; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; BMS; Merck Serono
 
Farshid Dayyani
Employment - Roche (I)
Consulting or Advisory Role - Array BioPharma; Eisai; Exelixis; Genentech/Roche; QED Therapeutics; Signatera
Speakers' Bureau - Amgen; Deciphera; Eisai; Exelixis; Genentech/Roche; ipsen; Natera; SERVIER; Sirtex Medical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech (Inst); Ipsen (Inst); Merck (Inst); Taiho Pharmaceutical (Inst)
 
Wells A. Messersmith
Consulting or Advisory Role - Five Prime Therapeutics (Inst); QED Therapeutics
Research Funding - Alexo Therapeutics (Inst); Beigene (Inst); D3 (Inst); Immunomedics (Inst); OncoMed (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
 
Nkiruka Ezenwajiaku
No Relationships to Disclose
 
Paul Eliezer Oberstein
Consulting or Advisory Role - AstraZeneca; Delcath Systems; Merck; QED Therapeutics; Rubius Therapeutics
Speakers' Bureau - AstraZeneca
Research Funding - Arcus Biosciences (Inst); Merck (Inst); Rafael Pharmaceuticals (Inst); Roche/Genentech (Inst)
Expert Testimony - Ipsen
Travel, Accommodations, Expenses - Merck
 
Ravi Kumar Paluri
Honoraria - Amgen; Ipsen
Speakers' Bureau - Ipsen
 
Reema Anil Patel
Honoraria - Onc Live
Research Funding - Genentech (Inst); Ipsen (Inst)
Travel, Accommodations, Expenses - Genentech
 
Edward Kim
Consulting or Advisory Role - Eisai; Lilly; Taiho Oncology
Speakers' Bureau - Eisai
Research Funding - Astellas Pharma (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Dynavax Technologies (Inst); EpicentRx (Inst); Erytech Pharma (Inst); Eureka Therapeutics (Inst); FibroGen (Inst); Halozyme (Inst); Merck (Inst); NGM Biopharmaceuticals (Inst); OncoMed (Inst); Samumed (Inst)
 
Aparna Kalyan
Honoraria - Samumed
Consulting or Advisory Role - Boston Scientific; Bristol-Myers Squibb; BTG; Eisai; Exelixis; Ipsen
Speakers' Bureau - Exelixis
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Exelixis
 
Brandon George Smaglo
Speakers' Bureau - Sirtex Medical; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Marker Therapeutics
 
Manik A. Amin
No Relationships to Disclose
 
Mohammed Najeeb Al Hallak
Speakers' Bureau - Ipsen
 
Olumide B. Gbolahan
Stock and Other Ownership Interests - Pfizer
Consulting or Advisory Role - Exelixis; Incyte; Merck Sharp & Dohme; QED Therapeutics
Speakers' Bureau - OncLive/MJH Life Sciences
Research Funding - AstraZeneca/MedImmune (Inst)
 
Lillian L. Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Amgen; Arvinas; AstraZeneca/MedImmune; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Hookipa Pharma; InterRNA; Janpix; Janssen; Merck; Navire; Oncorus; Relay Therapeutics; Roche; Sanofi; Seagen; Tessa Therapeutics; Voronoi Health Analytics
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst)
 
Jeffrey Moscow
No Relationships to Disclose
 
Anna Spreafico
Honoraria - Bristol-Myers Squibb; Medison & Immunocore
Consulting or Advisory Role - Bristol-Myers Squibb; Medison & Immunocore; Merck; Novartis; Oncorus
Research Funding - Alkermes; Amgen (Inst); Array BioPharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Merck; Northern Biologics; Novartis; Replimune; Roche; Surface Oncology; Symphogen; Treadwell Therapeutics (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Idera; Janssen Oncology; Merck; Roche